<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02323685</url>
  </required_header>
  <id_info>
    <org_study_id>SGCI-002</org_study_id>
    <nct_id>NCT02323685</nct_id>
  </id_info>
  <brief_title>Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) Following Subarachnoid Hemorrhage (SAH)</brief_title>
  <official_title>Single Escalating-dose, Open-label Study to Assess the Safety and Effect of SANGUINATE™ Infusion in Patients at Risk of Delayed Cerebral Ischemia (DCI) After Acute Aneurysmal Subarachnoid Hemorrhage (SAH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Prolong Pharmaceuticals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Prolong Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Safety and effect of SANGUINATE on patients DCI following SAH.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to study the safety and effect of SANGUINATE on patients
      suffering from delayed cerebral ischemia after acute aneurysmal subarachnoid hemorrhage.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">October 2016</completion_date>
  <primary_completion_date type="Actual">June 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of study drug during and following infusion as measured by vital signs, clinical signs, bioanalytical measures, or investigational drug-related adverse events</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Safety assessments to include vital signs, clinical signs, bioanalytical measures, or investigational drug-related adverse events</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Impact of SANGUINATE on brain oxygenation and blood flow assessed using Postitron Emission Tomography (PET)</measure>
    <time_frame>Up to 30 days</time_frame>
    <description>Blood oxygenation and blood flow will be assessed using Postitron Emission Tomography (PET)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in neurological function measured by National Institutes of Health Stroke Scale (NIHSS)</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence, location, and size of cerebral infarction as measured by MRI</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in Blood Gases as measured by Hemoximetry</measure>
    <time_frame>Up to 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Cerebral Ischemia</condition>
  <arm_group>
    <arm_group_label>SANGUINATE™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single infusion of SANGUINATE (pegylated carboxyhemogloblin)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>SANGUINATE™</intervention_name>
    <description>Single infusion of SANGUINATE (pegylated carboxyhemogloblin)</description>
    <arm_group_label>SANGUINATE™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed and dated written informed consent by the subject or his/her legally authorized
             representative;

          -  Modified Rankin (mRankin) score of 0 or 1 prior to the onset of subarachnoid
             hemorrhage;

          -  Ruptured aneurysm secured by endovascular coil embolization or surgical clipping (the
             Procedure), not more than 72 hours after the onset of subarachnoid hemorrhage; and

          -  Hunt and Hess (H&amp;H) grade 3 or 4, or World Federation of Neurological Surgeons (WFNS)
             score 3 or 4 prior to the Procedure, and Modified Fisher (mFisher) grade 3 or 4, prior
             to the Procedure; or

          -  Clinical signs of (&quot;symptomatic&quot;) delayed cerebral ischemia; or

          -  Angiographic evidence of cerebral vasospasm

        Exclusion Criteria:

          -  In the judgment of the Investigator the patient is not a good candidate for the study

          -  Evidence of rebleed following the Procedure

          -  Subarachnoid hemorrhage secondary to trauma or to arteriovenous malformation

          -  Diagnosed moderate to severe pulmonary hypertension

          -  Radiologically confirmed moderate to severe pulmonary edema (as shown by the presence
             of Kerley lines, peribronchial cuffing, thickened interlobar fissure, consolidation
             and/or pleural effusion)

          -  History within the past 6 months and/or finding of decompensated heart failure

          -  Acute myocardial infarction within 3 months prior to the administration of the study
             drug

          -  Left ventricular ejection fraction &lt;40%, as determined by prior echocardiography or
             clinical signs of CHF

          -  Medical history or concurrent evidence of moderate to severe renal insufficiency
             (estimated creatinine clearance &lt; 30 mL/min)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael N Dirringer, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Barnes Jewish Hospital/Washington University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rajat Dhar, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Barnes Jewish Hospital/Washington University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Barnes Jewish Hospital/Washington University</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 12, 2014</study_first_submitted>
  <study_first_submitted_qc>December 22, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 23, 2014</study_first_posted>
  <last_update_submitted>October 26, 2016</last_update_submitted>
  <last_update_submitted_qc>October 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DCI</keyword>
  <keyword>Delayed Cerebral Ischemia</keyword>
  <keyword>SAH</keyword>
  <keyword>Subarachnoid Hemorrhage</keyword>
  <keyword>Aneurysmal Subarachnoid Hemorrhage</keyword>
  <keyword>Cerebral Ischemia</keyword>
  <keyword>Brain Ischemia</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Subarachnoid Hemorrhage</mesh_term>
    <mesh_term>Brain Ischemia</mesh_term>
    <mesh_term>Cerebral Infarction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

